Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.01−0.09 (-8.18%)
Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%
Tvardi Therapeutics cash
Cash and short-term investments held at the end of each period.
Tvardi Therapeutics's cash was $15.77M at Jun 30, 2026. For fiscal 2025 it was $30.81M, down 18.7% from the year before. Over ten years it grew -11.7% a year on average. The highest annual figure on record is $251.49M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.81M | -18.7% |
| FY2024 | Dec 31, 2024 | $37.90M | -62.4% |
| FY2023 | Dec 31, 2023 | $100.76M | -35.7% |
| FY2022 | Dec 31, 2022 | $156.75M | -33.8% |
| FY2021 | Dec 31, 2021 | $236.79M | -5.8% |
| FY2020 | Dec 31, 2020 | $251.49M | +15.3% |
| FY2019 | Dec 31, 2019 | $218.17M | +19.4% |
| FY2018 | Dec 31, 2018 | $182.78M | +97.5% |
| FY2017 | Dec 31, 2017 | $92.57M | +58.8% |
| FY2016 | Dec 31, 2016 | $58.28M | -45.4% |
| FY2015 | Dec 31, 2015 | $106.74M | +102.7% |
| FY2014 | Dec 31, 2014 | $52.66M | +326.2% |
| FY2013 | Dec 31, 2013 | $12.36M | +1006.3% |
| FY2012 | Dec 31, 2012 | $1.12M | -72.7% |
| FY2011 | Dec 31, 2011 | $4.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.77M | -61.5% |
| Q1 FY2026 | Mar 31, 2026 | $24.98M | +118.4% |
| Q4 FY2025 | Dec 31, 2025 | $30.81M | -18.7% |
| Q3 FY2025 | Sep 30, 2025 | $36.46M | -13.3% |
| Q2 FY2025 | Jun 30, 2025 | $40.99M | -27.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.44M | -83.6% |
| Q4 FY2024 | Dec 31, 2024 | $37.90M | -62.4% |
| Q3 FY2024 | Sep 30, 2024 | $42.04M | -49.5% |
| Q2 FY2024 | Jun 30, 2024 | $56.62M | -44.4% |
| Q1 FY2024 | Mar 31, 2024 | $69.77M | -43.4% |
| Q4 FY2023 | Dec 31, 2023 | $100.76M | -35.7% |
| Q3 FY2023 | Sep 30, 2023 | $83.29M | -53.6% |
| Q2 FY2023 | Jun 30, 2023 | $101.74M | -50.3% |
| Q1 FY2023 | Mar 31, 2023 | $123.36M | -41.1% |
| Q4 FY2022 | Dec 31, 2022 | $156.75M | -33.8% |
| Q3 FY2022 | Sep 30, 2022 | $179.53M | -7.2% |
| Q2 FY2022 | Jun 30, 2022 | $204.68M | -1.3% |
| Q1 FY2022 | Mar 31, 2022 | $209.57M | -8.2% |
| Q4 FY2021 | Dec 31, 2021 | $236.79M | -5.8% |
| Q3 FY2021 | Sep 30, 2021 | $193.42M | +47.2% |
| Q2 FY2021 | Jun 30, 2021 | $207.39M | +35.5% |
| Q1 FY2021 | Mar 31, 2021 | $228.31M | +27.0% |
| Q4 FY2020 | Dec 31, 2020 | $251.49M | +15.3% |
| Q3 FY2020 | Sep 30, 2020 | $131.38M | -47.3% |
| Q2 FY2020 | Jun 30, 2020 | $153.05M | +12.8% |
| Q1 FY2020 | Mar 31, 2020 | $179.76M | +15.1% |
| Q4 FY2019 | Dec 31, 2019 | $218.17M | +19.4% |
| Q3 FY2019 | Sep 30, 2019 | $249.07M | +20.9% |
| Q2 FY2019 | Jun 30, 2019 | $135.63M | +2.8% |
| Q1 FY2019 | Mar 31, 2019 | $156.14M | +109.5% |
| Q4 FY2018 | Dec 31, 2018 | $182.78M | +97.5% |
| Q3 FY2018 | Sep 30, 2018 | $206.08M | +100.1% |
| Q2 FY2018 | Jun 30, 2018 | $131.96M | +17.4% |
| Q1 FY2018 | Mar 31, 2018 | $74.52M | +102.4% |
| Q4 FY2017 | Dec 31, 2017 | $92.57M | +58.8% |
| Q3 FY2017 | Sep 30, 2017 | $102.98M | +44.2% |
| Q2 FY2017 | Jun 30, 2017 | $112.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.81M | – |
| Q4 FY2016 | Dec 31, 2016 | $58.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $71.42M | – |
See a number that looks wrong?